Phase I Study of the Genital Immune Response to Live, Attenuated HSV529 Vaccine in HSV-2 Seropositive Adults

Trial Profile

Phase I Study of the Genital Immune Response to Live, Attenuated HSV529 Vaccine in HSV-2 Seropositive Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs ACAM 529 (Primary) ; Valaciclovir
  • Indications Herpes simplex virus type 2 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 01 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 05 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 13 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top